Assessing the Relationship Between Adverse Events and Investigational Products

Introduction: Why AE–IP Relationship Matters

In clinical trials, one of the most important judgments investigators and sponsors make is whether an adverse event (AE) is related to the investigational product (IP). Regulatory authorities such as the FDA, EMA, MHRA, and ICH guidelines require clear attribution of AEs to the IP, as this impacts expedited reporting, aggregate analyses, drug labeling, and ultimately the benefit–risk assessment of the product. Misclassification of causality can delay safety reporting, distort clinical trial outcomes, and trigger regulatory findings.

Assessing the relationship between AEs and investigational products requires both clinical judgment and systematic methods. This includes reviewing timing, dechallenge/rechallenge data, biological plausibility, and concomitant factors such as underlying disease and concomitant medications. The decision-making process must be documented, transparent, and consistent across all trial sites. This article provides a step-by-step guide on assessing AE–IP relationships, regulatory expectations, examples, challenges, and best practices.

Key Criteria for Determining Relationship to Investigational Product

Investigators and sponsors typically use structured criteria to determine whether an AE is related to the IP:

• Temporal relationship: Did the AE occur shortly after IP administration?
• Dechallenge: Did the AE resolve after stopping or reducing the IP?
• Rechallenge: Did the AE reappear when the IP was restarted?
• Biological plausibility: Is the AE consistent with the pharmacology of the IP?
• Alternative explanations: Could underlying disease, concomitant medication, or procedure explain the AE?

For example, if a subject develops elevated liver enzymes two weeks after starting the IP, and the levels normalize after discontinuation, a “probable” relationship may be established.

Regulatory Requirements for Causality Determination

Authorities emphasize that AE–IP relationships must be consistently documented and justified:

• FDA: Expects causality attribution in IND safety reports and NDA/BLA submissions, with reconciliation across datasets.
• EMA: Requires investigator and sponsor causality in EudraVigilance SUSAR submissions.
• MHRA: Frequently inspects eCRFs and SAE narratives to verify rationale for causality judgments.
• ICH E2A/E2B: Defines causality attribution as a mandatory field in safety reporting standards.

For example, in a 2022 EMA inspection, a sponsor was cited for failing to reconcile investigator-assessed “Not related” AEs with sponsor-identified safety signals in aggregate data, highlighting the importance of transparent reconciliation.

Case Study: Rash Following Immunotherapy

In a Phase II immunotherapy trial, several patients experienced Grade 3 skin rash. Investigators initially recorded the AEs as “Possibly related” to the IP. However, sponsor pharmacovigilance review noted a consistent pattern across multiple patients and classified the events as “Probably related.” The sponsor reported the rashes as SUSARs within 15 days. This proactive reclassification aligned with regulatory expectations and avoided inspection findings.

Challenges in Assessing AE–IP Relationship

Determining whether an AE is related to an investigational product is complex, with several challenges:

• Subjectivity: Different investigators may assess causality differently without training.
• Limited data: In early-phase trials, limited knowledge of the IP’s safety profile complicates judgments.
• Multiple confounders: Concomitant medications and comorbidities can obscure attribution.
• Bias: Investigators may underreport IP-related causality to protect trial continuation.

These challenges underline the need for structured tools (e.g., WHO-UMC scale) and sponsor oversight to ensure objective and consistent assessments.

Best Practices for Establishing AE–IP Relationship

To ensure accuracy and compliance, sponsors and investigators should adopt best practices:

• Use standardized causality assessment tools such as WHO-UMC scale or Naranjo algorithm.
• Require justification for each causality classification in eCRFs.
• Reconcile investigator and sponsor causality in safety databases and narratives.
• Establish SOPs for causality reassessment after unblinding in blinded trials.
• Train investigators and CRAs on causality documentation and regulatory expectations.

For example, in a cardiovascular trial, causality training modules were implemented for investigators, reducing misclassification and inspection findings by 40%.

Regulatory Implications of Misclassification

Incorrect AE–IP causality classification can have serious regulatory consequences:

• Delayed or missed SUSAR reporting.
• Incorrect DSUR/PSUR submissions.
• Inspection findings and regulatory citations.
• Potential delays in trial approval or marketing applications.

Accurate causality assignment is therefore essential not only for compliance but also for ensuring patient safety and maintaining trial credibility.

Key Takeaways

The relationship of adverse events to investigational products is central to clinical trial safety oversight. To ensure accuracy and compliance, sponsors and investigators must:

• Apply structured causality assessment tools.
• Document rationale for AE–IP relationship judgments.
• Reconcile investigator and sponsor causality assessments.
• Train stakeholders on regulatory expectations and best practices.

By applying these practices, trial teams can improve causality accuracy, strengthen regulatory compliance, and protect patient safety across global clinical development programs.

Understanding Investigator and Sponsor Roles in Causality Assessment

Introduction: Why Causality Roles Must Be Defined

Causality assessment is central to determining whether an adverse event (AE) is related to an investigational product (IP) in a clinical trial. Both investigators and sponsors play crucial roles in this process, but their responsibilities are distinct. Regulators such as the FDA, EMA, MHRA, and ICH guidance clearly outline the expectations for each stakeholder. Misalignment or poor documentation between investigator and sponsor causality assessments is one of the most common findings in regulatory inspections.

Investigators are closest to the patient and have first-hand clinical knowledge, while sponsors provide centralized oversight, pharmacovigilance expertise, and access to aggregate safety data. Both perspectives are necessary to ensure an accurate and comprehensive causality judgment. This article explores the responsibilities of investigators and sponsors, regulatory requirements, common challenges, and best practices for aligning causality assessments in clinical trials.

Investigator’s Role in Causality Assessment

The investigator is the primary medical professional responsible for patient care during the trial. Their role in causality assessment includes:

• First-hand evaluation: Reviewing the clinical presentation of the AE, including timing, lab results, and medical history.
• Initial judgment: Recording causality in the eCRF, typically using options such as “Related,” “Possibly related,” or “Not related.”
• On-site data review: Comparing the AE against concomitant medications, procedures, and disease progression.
• Documentation: Providing narrative justification in the medical notes or case report form.

For example, if a patient in an oncology trial develops neutropenia, the investigator must decide whether the condition is likely caused by the investigational chemotherapy agent or by underlying disease. Their judgment forms the first step of causality assessment.

Sponsor’s Role in Causality Assessment

While investigators provide the frontline assessment, sponsors are responsible for ensuring the accuracy and consistency of causality across the trial. Sponsor responsibilities include:

• Aggregate analysis: Reviewing AEs across all patients and sites to identify safety patterns.
• Medical review: Pharmacovigilance physicians re-assess causality using broader datasets, literature, and drug mechanism knowledge.
• Regulatory submissions: Ensuring that causality is consistent in SAE narratives, SUSAR reports, and databases such as EudraVigilance.
• Oversight: Ensuring that investigator assessments are complete, logical, and aligned with protocol and safety profiles.

For instance, if multiple sites report “hepatotoxicity” as unrelated, but the sponsor sees a safety signal across pooled data, the sponsor may classify these events as “possibly related” in regulatory submissions.

Reconciling Investigator and Sponsor Assessments

Discrepancies between investigator and sponsor causality assessments are common. Regulators expect sponsors to reconcile differences transparently. Best practices include:

• Maintaining both assessments in the safety database with clear attribution.
• Explaining differences in SUSAR reports or DSURs.
• Documenting the rationale for sponsor reclassification, supported by aggregate evidence.

For example, during a Phase III cardiovascular trial, investigators recorded myocardial infarction as “not related.” However, sponsor analysis across multiple cases suggested a potential safety signal, leading the sponsor to report the event as “possibly related” in regulatory filings.

Regulatory Expectations for Defined Roles

Authorities emphasize clear delineation of roles in causality assessment:

• FDA: Requires investigator causality assessments in IND safety reports, while allowing sponsors to provide independent judgment.
• EMA: Mandates inclusion of both investigator and sponsor causality in EudraVigilance submissions for SUSARs.
• MHRA: Inspections often highlight insufficient documentation of differences between assessments.
• ICH E2A: Reinforces the need for both local (investigator) and global (sponsor) perspectives in causality attribution.

During inspections, regulators often request side-by-side listings of investigator vs sponsor causality judgments, verifying whether discrepancies are justified and explained.

Challenges in Managing Roles

Several challenges complicate the division of roles in causality assessment:

• Subjectivity: Investigators may underreport causality due to bias toward investigational products.
• Data gaps: Sponsors may lack real-time clinical context when making aggregate judgments.
• Communication barriers: Sponsors and sites may not align on causality definitions or expectations.
• Inspection risk: Regulators may issue findings if discrepancies are not adequately reconciled.

These challenges highlight the need for SOPs, training, and clear documentation practices.

Best Practices for Harmonizing Investigator and Sponsor Roles

To ensure alignment and compliance, best practices include:

• Train investigators on standardized causality assessment tools such as WHO-UMC or Naranjo.
• Require written rationale for all causality classifications in eCRFs.
• Establish reconciliation workflows for sponsor vs investigator differences.
• Document causality rationale in SAE narratives and regulatory submissions.
• Conduct regular safety review meetings involving investigators and sponsor safety teams.

For example, in a global oncology trial, sponsors implemented joint causality review calls with investigators, reducing discrepancies and inspection findings.

Key Takeaways

Causality assessment requires active participation from both investigators and sponsors. Investigators provide patient-level clinical insights, while sponsors contribute aggregate data and regulatory oversight. Successful management of causality roles involves:

• Clear definition of responsibilities.
• Transparent reconciliation of differences.
• Documentation of rationale for all causality judgments.
• Training and communication to ensure consistency across the trial.

By following these practices, sponsors and investigators can align on causality assessments, meet regulatory expectations, and ensure accurate safety reporting.